

Family research of microbes linked to respiratory infections

Submission date 16/09/2020	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 24/09/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 23/03/2021	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study aims to learn more about how healthy adults and children are protected, or not, against respiratory infections. Many children and adults carry bacteria in their noses and mouth. We constantly share these bacteria with our family members. The types and numbers of bacteria we carry change with our age and lifestyle habits. This change makes some people sharing households more likely to get a respiratory infection. It is hoped that in this study, by studying bacteria in the nose and mouth of family members and how different factors influence their change over time, this information can be used to better prevent and treat respiratory infections in the future.

The study team has developed an easy to use a sampling technique to self-collect saliva and fluid close to the lining of the nose at home. The study aims to find out if it is practical for families to collect these samples at home.

Who can participate?

Families of 4 members, with two adults aged 18-60 years, and two children aged 28 days-17 years, who are generally healthy.

What does the study involve?

A trained clinician will show participants how to collect samples of fluid from inside the nose, a small amount of saliva, and hand swabs, from both themselves and their children. Families will be then asked to collect samples themselves at home every 2 weeks for 6 months for all participating members.

What are the possible benefits and risks of participating?

While this study will not benefit families directly, it may help us to understand more about how healthy people are protected from respiratory infections to help us to prevent these in the future. We do not expect any discomfort as sampling techniques are not invasive. Eyes may sometimes water after placing the paper strip in the nose.

Where is the study run from?

Liverpool School of Tropical Medicine (UK) and Alder Hey Children's NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
From May 2020 to August 2021

Who is funding the study?
The Liverpool School of Tropical Medicine (UK)

Who is the main contact?
Dr Elissavet Nikolaou
elissavet.nikolaou@lstmed.ac.uk.

Contact information

Type(s)

Public

Contact name

Dr Elissavet Nikolaou

ORCID ID

<http://orcid.org/0000-0003-4797-4710>

Contact details

Respiratory Infection Group
Department of Clinical Sciences
Liverpool School of Tropical Medicine
1st Daulby Street
Liverpool
United Kingdom
L7 8XZ
+44 (0)151 702 9346
elissavet.nikolaou@lstmed.ac.uk

Type(s)

Scientific

Contact name

Dr Andrea Collins

ORCID ID

<http://orcid.org/0000-0002-4094-1572>

Contact details

Respiratory Infection Group
Department of Clinical Sciences
Liverpool School of Tropical Medicine
1st Daulby Street
Liverpool
United Kingdom

L7 8XZ
+44 (0)151 7029439
andrea.collins@lstmed.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

284708

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

IRAS 284708

Study information

Scientific Title

Establishment of home sampling as a surveillance tool for understanding the role of the human oral and nasal microbiota in respiratory disease

Acronym

FAMILY MICRO

Study objectives

1. Home sampling is an effective and community acceptable methodology for sampling children and their family members long-term
2. The microbiome plays an important role in respiratory disease occurrence and transmission within household members

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/09/2020, North West - Greater Manchester West Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)2071048384; gmwest.rec@hra.nhs.uk), ref: 20/NW/0304

Study design

Single-centre observational cross-sectional cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Home

Study type(s)

Diagnostic

Participant information sheet

See additional files

Health condition(s) or problem(s) studied

Understanding respiratory disease occurrence and transmission in households of healthy participants

Interventions

Adult participants will collect non-invasive mucosal samples from themselves and their children at home every 2 weeks for 6 months.

Participants will fill in questionnaires on demographics and epidemiological data at baseline, questionnaires describing practicality at each study day after sample collection, and keep a monthly diary of routine activities/habits.

Formative qualitative semi-structured interviews will be conducted at the end of the study, exploring the acceptability of the procedures.

Intervention Type

Other

Primary outcome measure

1. Feasibility determined by the percentage (%) compliance measured as the number of samples stored in the fridge/freezer per volunteer to the total number of participants, where samples are collected every 2 weeks between baseline and 6 months
2. Acceptability determined by the percentage (%) long-term acceptability measured using the practicality questionnaire to the total number of participants, where the questionnaire is completed every 2 weeks between baseline and 6 months

Secondary outcome measures

1. Microbiome taxonomic profiles will be generated by metagenomic 16S rRNA amplicon sequencing using Illumina technology of mucosal samples collected every 2 weeks between baseline and 6 months
2. Virome will be determined by multiplex qPCR of mucosal samples collected every 2 weeks between baseline and 6 months
3. Presence of AMR genes will be elucidated by conventional PCR of mucosal samples collected every 2 weeks between baseline and 6 months
4. Data will be related to epidemiological information and episodes of respiratory tract infection collected by epidemiological questionnaires completed by participants every 2 weeks between baseline and 6 months

Overall study start date

01/05/2020

Completion date

31/08/2021

Eligibility

Key inclusion criteria

1. Adults aged 18-60 years and their children aged 28 days–17 years
2. Parent with fluent spoken English - to ensure a comprehensive understanding of the research project and the proposed involvement
3. Capacity of the parent to give informed consent

Participant type(s)

Healthy volunteer

Age group

Mixed

Upper age limit

60 Years

Sex

Both

Target number of participants

We aim to recruit 32 families of 4 members so in total 128 participants (64 parents and 64 children). To account for dropouts or inadequate samples, this target will be adjusted to a maximum of 40 families (32 more participants, maximum 160 participants).

Total final enrolment

160

Key exclusion criteria

1. Taking daily medications that may affect the microbiome e.g. long-term antibiotics or immunosuppressants (including oral steroids)
2. Having received immunosuppressants or antibiotics in the preceding 28 days (recruitment can be delayed until the 28 days have passed)
3. History of respiratory infections requiring hospitalisation
4. Involved in a CTIMP or any trial that can affect the microbiome.
5. Disease or syndrome associated with altered immunity or altered respiratory or gut microbiome (including Crohn's disease, ulcerative colitis or diabetes, and asthma or COPD) or other RTI conditions (including cystic fibrosis or bronchiectasis)
6. Current severe acute respiratory infection
7. Children with cognitive disabilities that lead to an inability to comply with study sampling

Date of first enrolment

01/10/2020

Date of final enrolment

28/02/2021

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Liverpool School of Tropical Medicine

Liverpool Life Sciences Accelerator Building

1 Daulby Street

Liverpool

United Kingdom

L7 8XZ

Study participating centre

Alder Hey Children's NHS Foundation Trust

East Prescott Rd

Liverpool

United Kingdom

L14 5AB

Sponsor information

Organisation

Liverpool School of Tropical Medicine

Sponsor details

Research Governance and Ethics Office

2nd Floor LLSA

1 Daulby Street

Liverpool

United Kingdom

L7 8XZ

+44 (0)151 702 9562

lstmgov@lstmed.ac.uk

Sponsor type

Charity

Website

<http://www.lstmed.ac.uk>

Funder(s)

Funder type

University/education

Funder Name

Liverpool School of Tropical Medicine

Alternative Name(s)

LSTM

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

We will produce a lay report of our findings, which will be made available to all participants on the LSTM website. The findings from this study will be shared among the scientific community by publishing our findings in peer-reviewed open-access scientific journals and presenting data at appropriate local, national and international conferences.

Intention to publish date

01/01/2022

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version v3.0	18/09/2020	08/10/2020	No	Yes
Participant information sheet	version v2.0	04/09/2020	08/10/2020	No	Yes
Participant information sheet	version v3.0	18/09/2020	08/10/2020	No	Yes
HRA research summary			28/06/2023	No	No